Eccentric overload muscle damage is attenuated by a novel angiotensin- (1-7) treatment.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorOliveira, Lenice Kappes Becker-
Autor(es): dc.creatorTotou, Nádia Lúcia-
Autor(es): dc.creatorMoura, Samara Silva de-
Autor(es): dc.creatorKangussu, Lucas Miranda-
Autor(es): dc.creatorSinisterra Millán, Ruben Dario-
Autor(es): dc.creatorSantos, Maria Jose Campagnole dos-
Autor(es): dc.creatorCoelho, Daniel Barbosa-
Autor(es): dc.creatorSantos, Daisy Motta-
Autor(es): dc.creatorSantos, Robson Augusto Souza dos-
Data de aceite: dc.date.accessioned2025-08-21T15:12:23Z-
Data de disponibilização: dc.date.available2025-08-21T15:12:23Z-
Data de envio: dc.date.issued2019-04-25-
Data de envio: dc.date.issued2019-04-25-
Data de envio: dc.date.issued2018-
Fonte completa do material: dc.identifierhttp://www.repositorio.ufop.br/handle/123456789/11126-
Fonte completa do material: dc.identifierhttps://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-0633-8892-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1005813-
Descrição: dc.descriptionThe development of new strategies to attenuate exercise-induced muscle damage may be helpful for training regimens. The aim of this study was to determine whether a oral formulation of angiotensin Ang-(1-7)[HPβCD/Ang-(1-7)] is effective to reduce pain, and muscle damage markers after eccentric-overload exercise. HPβCD (Placebo) and HPβCD/Ang-(1-7) (Ang-(1-7) group were treated for 7 days (one capsule/day). The pain was measured by visual analogue scale, maximal strength (MS) using force platform. Blood samples were collected for cytokines and creatine kinase (CK) analysis. The Ang-(1-7)-treated group reported less pain immediately (3.46± 0.64 vs. placebo 3.80± 0.77 cm) and 24h after exercise (3.07±0.71 vs. 3.73±0.58cm placebo) and higher MS at 24h (24±12N) and 48h (30±15N) vs. placebo (-8 ± 9 N and -10 ± 9 N). The CK for Ang-(1-7) (0.5 ± 0.1 and 0.9±0.2 U/L) were lower at 48 and 72h vs. placebo (fold changes of 1.7±0.5 and 1.5±0.3 U/L). The TNF-α level was lower in the treated group post-exercise (38 ± 2.5 pg/ml) vs. placebo (45 ± 2.9 pg/ml) but no significant changes were observed for IL-6 and IL-10. Our data indicate that treatment with Ang-(1-7) may attenuate pain, some of the muscle damage markers and improves performance following eccentric exercise.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsrestrito-
Palavras-chave: dc.subjectPhysical performance-
Palavras-chave: dc.subjectMuscular damage-
Título: dc.titleEccentric overload muscle damage is attenuated by a novel angiotensin- (1-7) treatment.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.